1-Boc-4-piperidinamidine

Catalog No.: 
ACJAQP280
CAS No.: 
885270-23-5
Molecular Formula: 
C11H21N3O2
Molecular Weight: 
227.31
1-Boc-4-piperidinamidine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$66.00In stockInquiry
5g95%$310.00In stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Boc-4-piperidinamidine
IUPAC Nametert-butyl 4-carbamimidoylpiperidine-1-carboxylate
MDL No.MFCD05663956
Molecular FormulaC11H21N3O2
Molecular Weight227.31
SMILESNC(C1CCN(C(OC(C)(C)C)=O)CC1)=N
InChI KeyZDZXZKQTFNUKKG-UHFFFAOYSA-N
Synonymtert-butyl 4-amidinopiperidine-1-carboxylate;1-Boc-4- carbamimidoylpiperidine;4-carbamimidoyl-1-piperidinecarboxylic acid tert-butyl ester;1-Boc-4-piperidinamidine;1-Piperidinecarboxylic acid, 4-(aMinoiMinoMethyl)-, 1,1-diMethylethyl ester;1-Boc-4-AMidinopiperidine;1,1-Dimethylethyl 4-(aminoiminomethyl)-1-piperidinecarboxylate
CAS No.885270-23-5
PubChem CID44828660

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H332-H335
Precautionary Statement(s)
P261-P280-P305+P351+P338

Synthetic Route by SureRoute

1. ACJAQP280 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFQWE273 route compound structure diagram
    ACFQWE273280110-63-6In Stock
  2. Then
  3. ACJAQP280 route product structure diagram
    ACJAQP280885270-23-5In Stock
Inquiry

2. ACJAQP280 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACFPBN379 route compound structure diagram
    ACFPBN37991419-48-6
  2. Then
  3. ACJAQP280 route product structure diagram
    ACJAQP280885270-23-5In Stock
Inquiry

3. ACJAQP280 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJAQP280 route product structure diagram
    ACJAQP280885270-23-5In Stock
Inquiry

Comments (0)